Proclaim — Implementation Playbook (DSO)

Proclaim Personalized Oral Irrigator Implementation Playbook

A Strategic Guide for DSO Operators

Prepared for: VPs of Clinical Affairs, Chief Dental Officers, VP of Operations Organization Type: Dental Service Organizations (5–50 Locations) Tool Category: Personalized Preventive Device / Adjunctive Hygiene Version: 1.0 | Publication Date: 2026

1. Executive Summary

What Proclaim Does

Proclaim, by Fresh Health, is a dentist-prescribed custom oral irrigator. Using data from intraoral scans and 3D printing, Fresh Health manufactures a personalized nozzle for each patient — one that delivers water jets precisely to that patient's unique interdental geometry. The patient uses the device at home; the prescription originates at the dental practice.

For a DSO, Proclaim is a preventive adjunct tool that could be layered into hygiene appointment workflows across locations. The strategic questions are different from the solo practice evaluation: Can the platform scale across locations with diverse intraoral scanner ecosystems? Is there a meaningful per-location revenue contribution that justifies the training and workflow integration cost? Does Proclaim support DSO-level reporting on prescription volume and patient outcomes?

As of 2026, Proclaim is in early commercial deployment through a select network of practices. DSOs considering engagement are doing so at an early stage — this is a clinical innovation adoption decision, not a mature product rollout, and it should be evaluated accordingly.

Why DSOs Might Offer This

Expected Timeline: Decision to Portfolio Deployment

• Month 1: Vendor diligence, scanner compatibility audit, legal review
• Month 2–3: Pilot deployment at 3–5 locations, training, workflow validation
• Month 4–6: Pilot evaluation, decision on portfolio expansion
• Month 6+: Portfolio rollout if pilot outcomes support expansion

2. Pre-Implementation Checklist

• ☐ IOS compatibility audit: Inventory all intraoral scanner models in use across your locations; confirm Proclaim's compatibility with each (TRIOS, iTero, Medit, Carestream, etc.)
• ☐ Clinical evidence review: Chief Dental Officer should review available clinical data before portfolio adoption; the standard for a multi-location rollout is higher than for a solo practice
• ☐ Revenue model documentation: Get the practice economics in writing — prescription fee, subscription revenue share, and volume tiers — before committing to a pilot
• ☐ FDA clearance and regulatory status: Confirm device clearance; engage regulatory counsel if custom device regulatory status is unclear
• ☐ Centralized prescription workflow: Determine whether prescription submission will be managed at the location level or routed through a central clinical team
• ☐ Training delivery model: Decide between vendor-led per-location training vs. train-the-trainer approach through a central clinical team
• ☐ Patient cost communication: Standardize how the device cost and subscription are presented to patients across all locations
• ☐ PMS documentation standard: Establish a consistent method for documenting Proclaim prescriptions across your PMS platforms
• ☐ Pilot location selection: Choose 3–5 locations with engaged hygiene teams, active IOS workflows, and a meaningful perio patient base
• ☐ Reporting expectations: Define what data Proclaim provides at the DSO level — prescription volume by location, patient activation rates, subscription retention

3. Implementation Phases

Phase 1: Audit and Vendor Alignment (Month 1)

Conduct an IOS compatibility audit across all locations. If your portfolio includes multiple scanner types — a common DSO reality — confirm that each is supported. Any locations with incompatible scanners or no scanner at all will need a separate pathway or exclusion from the program.

Work with your Chief Dental Officer and clinical leadership to review Proclaim's clinical rationale and available evidence. Establish internal clinical standards for which patients are appropriate candidates — this should be a defined, consistent protocol, not a per-hygienist judgment call.

Clarify the revenue model in writing. What does the practice earn per prescription? Is there any per-subscription revenue? At what volume do the economics justify the training and workflow investment?

Phase 2: Structured Pilot (Months 2–3)

Select pilot locations based on: active IOS workflow, engaged clinical leadership, and meaningful perio patient volume. Avoid pilots at locations with scanner compatibility issues or hygiene team instability — the pilot should be set up to succeed, not to test minimum viable conditions.

Train pilot location hygiene teams thoroughly. The hygienist is the prescriber in this workflow. They need to be confident in: the clinical rationale, the patient conversation, the scan submission process, and the follow-up protocol. Designate a hygiene champion at each pilot location who owns adoption and provides feedback.

Track prescription volume, patient activation rates (device ordered vs. used), and early perio metrics from month one.

Phase 3: Pilot Evaluation and Portfolio Decision (Months 4–6)

At the pilot review point, evaluate:

• Prescription volume: Are hygienists consistently identifying and prescribing to appropriate patients?
• Patient activation: Are prescribed patients actually receiving and using the device?
• Revenue contribution: Does the per-location revenue justify the ongoing training and workflow overhead?
• Clinical outcomes: Are there measurable perio improvements in Proclaim patients at the 3-month recall?
• Staff burden: Is the workflow addition sustainable and acceptable to hygiene teams?

This review drives the expand/hold/exit decision. Do not default to expansion based on enthusiasm alone — ground the decision in pilot data.

4. Integration Considerations

IOS ecosystem diversity: DSOs often have a mix of scanner types across locations. Proclaim must support all of them, or you will have a multi-tier rollout complexity — some locations on the program, some not — that creates training inconsistency and patient experience variation.

PMS documentation: Establish a standardized documentation method across all PMS systems in your portfolio. A Proclaim prescription should appear consistently in patient records regardless of which PMS a location uses.

Centralized reporting: Push Proclaim for a DSO-level dashboard or data export. You need to see prescription volume, patient activation, and subscription retention by location without pulling reports manually from each location's account.

Supply chain: Replacement tips and solution cartridges for patients should flow directly through Fresh Health, not through your locations. Confirm this so locations aren't managing inventory for a prescription device.

5. Pricing and ROI Framework

Proclaim's commercial pricing and practice economics may be negotiated at the DSO level. Push for volume-based incentives and multi-location contract terms.

DSO-level ROI modeling:

Example: 20 locations × 10 prescriptions/month × $50 per prescription = $10,000/month, or $120,000 annually. At that volume, the training investment is easily justified — but validate the $50 per prescription figure and the 10/month assumption independently.

6. Key Questions to Ask the Vendor

1. What intraoral scanner models are fully compatible, and what is the scan submission workflow for each?
2. What is the manufacturing and delivery turnaround from scan submission to device receipt?
3. What does the practice earn per prescription, and is there any ongoing subscription revenue share?
4. Do you offer DSO-level reporting — prescription volume, activation rate, subscription retention by location?
5. What clinical evidence (peer-reviewed) supports efficacy claims vs. conventional flossing or standard water flossing?
6. What volume-based pricing or DSO contract terms are available?
7. How do you handle patient support and device replacement — does that flow through Fresh Health or the practice?
8. What is your current production and distribution capacity — can you support a 20-location rollout?
9. Who are your largest DSO or multi-location practice customers, and can we speak with them?

7. Red Flags and Considerations

• IOS incompatibility at scale: If 30% of your locations are on an unsupported scanner, you cannot deploy consistently. This must be resolved before committing to a portfolio rollout.
• Clinical evidence gap: Peer-reviewed outcomes data comparing Proclaim vs. standard irrigation is limited as of 2026. Presenting a tool as clinically superior without published evidence creates a patient communication and regulatory risk.
• Early-stage supply chain: Fresh Health is a startup. Can they fulfill a 20-location DSO's prescription volume reliably? Ask about production capacity and fulfillment track record explicitly.
• Per-prescription revenue disappointment: If the economics turn out to be $15–20/prescription rather than $50+, the ROI picture changes materially. Validate this before building a business case.
• Patient price sensitivity across demographics: DSOs serving price-sensitive patient populations may find limited uptake for a premium prescription device. Match the program to the right locations in your portfolio.
• Hygienist adoption fatigue: Hygienists are asked to adopt new tools regularly. If this tool doesn't have a clear clinical champion in the hygiene team, adoption will be superficial and prescription volume will disappoint.

8. Avized Verdict

Proclaim is a clinically inventive product that fits naturally into the DSO hygiene appointment workflow — the scan data is already collected, the prescription is hygienist-driven, and the patient interaction is a natural extension of perio counseling. The DSO case is better than the solo practice case specifically because volume makes the economics more meaningful and the standardization infrastructure already exists.

The key risk is early-stage company reliability — manufacturing capacity, supply chain consistency, and clinical evidence maturity. DSOs should proceed with a structured pilot, validate the economics and clinical outcomes, and expand only with data in hand. Best suited for DSOs with a centralized hygiene clinical program, active IOS deployment across locations, and a patient base with meaningful perio disease burden.